Laura R.
- Country
- Italy
- Department
- UO Oncologia Medica
Research Overview
- Neoadjuvant Immunotherapy with Nivolumab, Ipilimumab, MDNA11, and Tocilizumab in High-Risk Resectable Melanoma: A Phase Ib Multicentre Randomised Trial
- Evaluation of Administration Route Preference for Nivolumab and Relatlimab in Melanoma Patients: Subcutaneous Versus Intravenous Delivery
- Evaluation of Safety and Tolerability of TransCon IL-2 β/γ, Pembrolizumab, and TransCon TLR7/8 Agonist in Advanced or Metastatic Solid Tumor Malignancies
Data & Insights
Has run more than one trial at 54 of 190 partner sites.
Specializations
Melanoma Research
The investigator specializes in treating various stages of melanoma, with particular focus on advanced and resectable cases. Their expertise extends to both BRAF-mutated and wild-type melanoma variants.
- Stage IIB, IIC, and III melanoma management
- Advanced metastatic melanoma treatment
- High-risk resectable melanoma
The investigator explores novel therapeutic approaches including immunotherapy combinations and administration routes.
Immunotherapy Applications
Focuses on innovative immunotherapeutic approaches including dendritic cell vaccines and combination therapies for various cancers.
- Autologous dendritic cell vaccination
- Tumor-specific immune responses
- Combination immunotherapy strategies
Investigates personalized vaccine approaches using patient-derived materials.
Diverse Oncology Focus
Extends research into multiple advanced cancer types, including rare and challenging malignancies.
- Glioblastoma treatment
- Mesothelioma management
- Neuroendocrine tumors
- Soft tissue sarcoma
Specializes in treating advanced solid tumors with novel therapeutic combinations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.